DAX24.092 +0,7%ESt505.376 +0,4%Top 10 Crypto14,16 +1,9%Dow42.520 +0,5%Nas19.399 +0,8%Bitcoin92.910 +0,3%Euro1,1375 ±-0,0%Öl65,42 -0,3%Gold3.363 +0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 RENK RENK73 BioNTech (ADRs) A2PSR2 NVIDIA 918422 HENSOLDT HAG000 Siemens Energy ENER6Y Tesla A1CX3T Lufthansa 823212 BYD A0M4W9 Gerresheimer A0LD6E BASF BASF11 Mercedes-Benz Group (ex Daimler) 710000 Bayer BAY001 Deutsche Bank 514000 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Dow letztlich fester -- DAX schließt höher - über 24.000 Punkten -- Palantir profitiert von möglichem Regierungsauftrag -- Rheinmetall, BYD, VW, Tesla im Fokus
Top News
NVIDIA-Aktie unter Druck: Läuft Huawei dem US-Chipriesen in China den Rang ab? NVIDIA-Aktie unter Druck: Läuft Huawei dem US-Chipriesen in China den Rang ab?
Dubai startet Immobilien-Tokenisierung mittels XRP Ledger Dubai startet Immobilien-Tokenisierung mittels XRP Ledger
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Syndax Pharmaceuticals Aktie

Handeln
Aktien-Sparplan anlegen
9,40 EUR -1,90 EUR -16,81 %
FSE
11,19 USD +0,21 USD +1,87 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.830,01 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2AFL6

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS87164F1057

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSNDX

Syndax Pharmaceuticals Aktien News

DatumMeistgelesen
finanzen.netSyndax Pharmaceuticals veröffentlichte Zahlen zum vergangenen Quartal
ZacksSyndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates
finanzen.netSyndax Pharmaceuticals: So viel setzte das Unternehmen zuletzt um
Wer­bungSyndax Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
ZacksSyndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Participation in February Investor Conferences
PR NewswireIncyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
PR NewswireSyndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireSyndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors
PR NewswireSyndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
PR NewswireSyndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Participation at the Citi 2024 Global Healthcare Conference
PR NewswireSyndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
BenzingaSyndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
PR NewswireSyndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
finanzen.netSyndax Pharmaceuticals mit Zahlen zum abgelaufenen Quartal
ZacksSyndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates
PR NewswireSyndax Reports Third Quarter 2024 Financial Results and Provides Business Update
PR NewswireSyndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
PR NewswireSyndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting
PR NewswireSyndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
PR NewswireSyndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Participation in November Investor Conferences
PR NewswireSyndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
PR NewswireSyndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
PR NewswireSyndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
PR NewswireSyndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Wer­bung

Syndax Pharmaceuticals News

Syndax Pharmaceuticals News: auf dieser Seite finden Sie alle Syndax Pharmaceuticals News und Nachrichten zur Syndax Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Syndax Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Syndax Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.